At a glance
ClinicalIndex Comparison RecordPhase 3Unknown· 250 target
Drug / intervention
MPs +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia in Patients With Acute Leukemia Receiving Chemotherapy
Nanfang Hospital, Southern Medical University·interventional·Posted Sep 16, 2014·Updated Sep 16, 2014
In Brief
A Phase 3 clinical trial evaluating MPs and thrombopoietin (TPO) and interleukin-11 for Hematological Diseases and Thrombocytopenia. Targeting 250 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the efficacy of ex vivo generated megakaryocytic progenitor cells (MPs) in prophylaxis and treatment of thrombocytopenia caused by chemotherapy in patients with acute leukemia (AL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematological Diseases, Thrombocytopenia
CountriesChina
CollaboratorsGuangdong Provincial People's Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou First People's Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Southern Medical University, China, Peking University People's Hospital, Huazhong University of Science and Technology, Sun Yat-sen University, Academy Military Medical Science, China
Timeline
Phase 3UnknownOverdue
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedSep 2014
Primary CompletionSep 2016
Study CompletionDec 2016
TodayJul 2026
First PostedSep 16, 2014
Enrollment StartSep 1, 2014
Primary CompletionSep 1, 2016
Study CompletionDec 1, 2016
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 11.8 years ago
Interventions
MPsbiological
MPs are generated from cord blood using a combination of cytokines.
thrombopoietin (TPO) and interleukin-11drug
Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.